Table 1.
Randomized trials comparing Rituximab-chemotherapy vs chemotherapy alone in follicular lymphoma patients
| Reference | Year | Prior treatment | Treatment | No of patients | ORR | OS | PFS |
| Marcus et al[3,4] | 2005, 2008 | No | R-CVP vs CVP | 321 | 81% vs 57% (P < 0.001) | 83% vs 77% at 4-years (P = 0.029) | 27 vs 7 mo ( P < 0.001) 1 |
| Hiddeman et al[5] | 2005 | No | R-CHOP vs CHOP | 428 | 96% vs 90% (P = 0.001) | 95% vs 90% at 2 yrs (P =0.016) | 91% vs 79% at 2 yrs ( P < 0.001)1 |
| van Oers et al[6,7] | 2006, 2010 | Yes | R-CHOP vs CHOP | 465 | 85% vs 72% (P < 0.001) | 82% vs 79% at 3 years (P = 0.09) | 33 vs 20 mo ( P < 0.001) |
| Forstpointner et al[10] | 2006 | Yes | R-FCM vs FCM | 125 | 95% vs 71% (P = 0.01) | Not available2 | Not available2 |
| Herold et al[9] | 2007, 2010 | No | R-MCP vs MCP | 358 | 92% vs 75% (P < 0.001) | 86% vs 74% at 5 years (P = 0.02) | 86 vs 35 mo ( P < 0.001) |
| Salles et al[8] | 2000 | No | R-CHVP-I vs CHVP-I | 358 | 94% vs 85% (P < 0.001) | 84% vs 79% at 5-years (P = 0.15) | 53% vs 37% at 5 years (P < 0.01) |
ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival;
1
Time-to-treatment-failure;
2
Data not available because of protocol design (double randomization).